Last reviewed · How we verify
Placebo+endocrine therapy
A combination therapy using placebo with endocrine therapy to treat hormone-responsive cancers by blocking estrogen or androgen signaling.
A combination therapy using placebo with endocrine therapy to treat hormone-responsive cancers by blocking estrogen or androgen signaling. Used for Hormone-responsive breast cancer (presumed, based on endocrine therapy use), Hormone-responsive prostate cancer (presumed, based on endocrine therapy use).
At a glance
| Generic name | Placebo+endocrine therapy |
|---|---|
| Also known as | Control group |
| Sponsor | Henan Cancer Hospital |
| Drug class | Endocrine therapy (aromatase inhibitor, selective estrogen receptor modulator, or androgen deprivation agent) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Endocrine therapy (such as aromatase inhibitors, tamoxifen, or androgen deprivation therapy) works by suppressing or blocking sex hormone receptors that drive growth of hormone-sensitive tumors. This Phase 3 trial appears to compare placebo plus endocrine therapy, likely as a control arm or to evaluate the endocrine therapy component in hormone-responsive cancers. The exact endocrine agent is not specified in the provided information.
Approved indications
- Hormone-responsive breast cancer (presumed, based on endocrine therapy use)
- Hormone-responsive prostate cancer (presumed, based on endocrine therapy use)
Common side effects
- Hot flashes
- Vaginal dryness or sexual dysfunction
- Bone loss / osteoporosis
- Fatigue
- Arthralgia
Key clinical trials
- Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study (PHASE3)
- A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) (PHASE3)
- A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy (PHASE3)
- An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS (PHASE3)
- A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity (PHASE1)
- Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. (PHASE3)
- Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer (PHASE2)
- A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo+endocrine therapy CI brief — competitive landscape report
- Placebo+endocrine therapy updates RSS · CI watch RSS
- Henan Cancer Hospital portfolio CI